NRX-101

Phase 1Small molecule

NNeuroRx, Inc.

NRX-101 is one of 11 small molecule programs targeting Major Depression. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Major DepressionRecruiting

Major DepressionPhase 1

Recruiting

Competition

Competitive Landscape

14 competitors in Major Depression

#DrugCompanyPhaseTrials

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Approved

5 2

Actemra

Roche

Phase 2

1 3

Psilocybin

COMPASS Pathways

Phase 3

3 4

Lexapro

SShirley Ryan AbilityLab

Preclinical

1 5

D-Cycloserine

MMassachusetts General Hospital

Preclinical

1 6

NRX-101

NNeuroRx, Inc.

Phase 1

1 7

SP-624

SSirtsei Pharmaceuticals, Inc.

Phase 1

1 8

Ropinirole CR

GSK

Preclinical

1 9

Choline Alphoscerate

SSamsung Medical Center

Preclinical

1 10

S-Adenosyl-L-Methionine

UUniversity Hospital, Basel, Switzerland

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Major Depression

NCT07785102

Q2 2028

PreclinicalRecruiting

Treatment Resistant Depression

NCT07227103

Clinical

Trials by Indication[1]

Suicidal Ideation2 trials

NRX-101 for Bipolar Depression With Subacute Suicidal Ideation

Completed·NNeuroRx, Inc.·Phase 2/3·NCT03395392·74 enrolled

NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation

Unknown status·NNeuroRx, Inc.·Phase 3·NCT03396068·72 enrolled

Treatment Resistant Depression2 trials

A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial

Recruiting·NNeuroRx, Inc.·Preclinical·NCT07227103·240 enrolled

NRX-101 for Treatment-Resistant Depression in Patients Receiving Transcranial Magnetic Stimulation Who Do Not Qualify for NRX101-011 (MIND1): Expanded Access Program

Available·NNeuroRx, Inc.··NCT05779267

Bipolar Depression1 trial

Sequential Therapy for the Treatment of Severe Bipolar Depression.

Completed·NNeuroRx, Inc.·Phase 2·NCT02974010·22 enrolled

Biomarker1 trial

NRX101 Glx Biomarker Validation Study

Completed·NNeuroRx, Inc.·Phase 2/3·NCT03402152·8 enrolled

Major Depression1 trial

SPARC-LI: Synaptic Plasticity Augmented Rapid Circuit Stimulation

Recruiting·MMclean Hospital·Phase 1·NCT07785102·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for NRX-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NRX-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NRX-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NeuroRx, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNeuroRx, Inc.

NRX-101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2028

Trials by Indication[1]

Suicidal Ideation2 trials

Treatment Resistant Depression2 trials

Bipolar Depression1 trial

Biomarker1 trial

Major Depression1 trial

References

Drug Info

Quick Facts

Related News